Amplia Therapeutics Limited (ASX: ATX), an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, has announced a capital raise of $27.5 million. FAK is an important target in cancer, with Amplia focusing on fibrotic cancers like pancreatic and ovarian cancer. The capital raise includes a $25 million institutional placement (Placement) and a share purchase plan (SPP) aiming to raise an additional $2.5 million. New shares under the Placement are priced at $0.23 each.
The Placement was strongly supported by existing and new institutional and sophisticated investors both in Australia and internationally. Amplia has also secured firm commitments from institutional investors for $2.5 million worth of shortfall shares under the SPP, ensuring the minimum target is met. The Placement Offer Price of $0.23 per New Share represents a 19.3% discount to the closing price of Amplia shares on Friday, 18 July 2025.
Funds from the Capital Raise will primarily support the ACCENT and AMPLICITY trials and further research into kRAS and ovarian cancer trials, all involving Amplia’s lead drug, narmafotinib (AMP945). The company anticipates top-line data from the ACCENT trial in late July or early August 2025. Following the capital injection, Amplia expects to be funded into 2027, enabling the company to accelerate towards commencement of a potential pivotal phase 2b/3 trial in the second half of 2026.
Amplia Managing Director Dr Chris Burns expressed gratitude for the support from both existing and new investors. He stated that the funds will support ongoing clinical studies and planning for follow-on trials, building on the data obtained for narmafotinib in the ACCENT study for pancreatic cancer. The company’s shares recommenced trading on the ASX today.
